Preventing Cervical Cancer With Hp v Vaccine

Gardacil nine was approved in two thousand and 14 for use in females and males aged 9 to 26 years. This reduces displasia due to hp v types 16 and 18, that accounts for about 75 % of cervical cancer. Types six and 11 are also reduced, thereby reducing anogenital warts. And it offers protection against five additional hp v types, which cause approximately 25% of c i n two lesions.